Objectives: Psoriatic arthritis (PsA) is associated with serious productivity impairment. Secukinumab, a fully human IL-17A inhibitor, provides sustained relief from PsA symptoms. This study estimates the societal economic benefits of using secukinumab instead of conventional disease-modifying anti-rheumatic drugs (DMARDs) for treating patients with active PsA in Germany from 2016 to 2030.
Methods: A Markov and a population model simulated the functional impairment of German PsA patients. The relationship between functional impairment and work productivity was used to determine the productivity difference in the populations treated with secukinumab and csDMARDs. The corresponding gains in productive time were allocated to paid and unpaid activities and valued according to gross value added (GVA). Since increased productivity has the potential to stimulate greater macroeconomic effects, indirect and induced GVA effects were calculated as well.
Results: The use of secukinumab reduces the productivity impairment in the target population on average by 13 percentage points. This difference could generate 32 million active and productive hours until the year 2030, which translates to GVA equivalents of €1.3 billion. Including indirect and induced effects yield an economic estimate of €2.7 billion GVA equivalent.
Conclusions: The improvements in PsA-related functional impairment could lead to sizable productivity effects within the economy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14737167.2019.1644169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intranasal Calcitriol Accelerates Improvement of Sinonasal Inflammation and Olfactory Impairment in Mice After Cessation of Chronic Cigarette-Smoke Exposure.
Int Forum Allergy Rhinol
January 2025
Division of Division of Rhinology & Skull Base Surgery Department of Otolaryngology, University of Florida, Gainesville, Florida, USA.
Rationale: Smoking has been shown to be associated with circulating deficiencies in 25(OH)D3 and reduced sinonasal tissue levels of the active form of vitamin D, 1,25(OH)2D3. Given vitamin D's ability to reduce inflammation, we sought to examine if intranasal (IN) delivery of calcitriol [clinical analog of 1,25(OH)2D3] could reduce inflammation and improve disease severity in a murine model of chronic cigarette smoke-induced sinonasal inflammation (CS-SI).
Methods: Mice were exposed to CS 5 h/day, 5 days/week for 9 months, and then began IN calcitriol three times per week for 4 weeks.
Antiamnesic and Neurotrophic Effects of (Jacq.) R. Br (Fabaceae) Aqueous Extract on In Vivo and In Vitro Models of Excitotoxicity.
Behav Neurol
January 2025
Department of Animal Biology and Physiology, University of Yaoundé I, Yaoundé, Cameroon.
Amnesia is a memory disorder marked by the inability to recall or acquire information. Hence, drugs that also target the neurogenesis process constitute a hope to discover a cure against memory disorders. This study is aimed at evaluating the antiamnesic and neurotrophic effects of the aqueous extract of () on in vivo and in vitro models of excitotoxicity.
View Article and Find Full Text PDFReconstructed Epidermis Produced with Atopic Dog Keratinocytes Only Exhibit Skin Barrier Defects after the Addition of Proinflammatory and Allergic Cytokines.
JID Innov
March 2025
Small Animal Clinic, École Nationale Vétérinaire de Toulouse, University of Toulouse, Toulouse, France.
Our objectives were to explore epidermal barrier defects in dogs with atopic dermatitis and to determine whether the defects are genetically determined or secondary to skin inflammation. First, the expression of filaggrin, corneodesmosin, and claudin1, analyzed using indirect immunofluorescence in skin biopsies collected from 32 healthy and 32 dogs with atopic dermatitis, was weaker in the atopic skin ( .003).
View Article and Find Full Text PDFComputerized cognitive testing to capture cognitive decline in Alzheimer's disease: Longitudinal findings from the ARMADA study.
Alzheimers Dement (Amst)
January 2025
Department of Neurology Massachusetts General Hospital, Harvard Medical School Boston Massachusetts USA.
Introduction: Timely detection and tracking of Alzheimer's disease (AD) -related cognitive decline has become a public health priority. We investigated whether the NIH Toolbox for Assessment of Neurological and Behavioral Function-Cognition Battery (NIHTB-CB) detects AD-related cognitive decline.
Methods: = 171 participants (age 76.
Modifiable risk factors and symptom progression in dementia over up to 8 years-Results of the DelpHi-MV trial.
Alzheimers Dement (Amst)
January 2025
Health Care Research Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Greifswald Mecklenburg-Vorpommern Germany.
Introduction: This study investigated the association between modifiable factors and symptom progression in dementia over up to 8 years.
Methods: Multilevel growth curve models assessed the role of modifiable risk factors (low education, hearing impairment and its treatment, depression, physical inactivity, diabetes and its treatment, smoking, hypertension and its treatment, obesity, alcohol consumption, social isolation, and visual impairment) on cognitive and functional trajectories in 353 people with dementia.
Results: Higher education was associated with higher initial cognitive status but faster decline.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!